

Special Issue

Research in Pelvic and Sacral Bone Sarcoma Diagnosis and Treatment

Message from the Guest Editors

The pelvis is a common area for the development of bony sarcomas. Resection of pelvic bone sarcomas is technically challenging due to the proximity of critical neurovascular structures, complex 3-dimensional anatomy, and adjacent organs. They are treated by a multidisciplinary team, and the decision to proceed with surgery, and the subsequent ultimate outcome of care, is based on tumor type, location, and operative plan. The incidence of these tumors has been increasing, with the most common histologies being chondrosarcoma, Ewing sarcoma, and osteosarcoma. When compared to the same tumor histology in the extremities, tumors located in the pelvis are known to have a poor prognosis, with a high rate of local recurrence and poor overall survival. Although prognosis is poor compared to the extremities, the only hope for cure in these patients requires a multidisciplinary approach. This Special Issue will provide highlights on the role of these newer medical and surgical advances in the care of this complex patient population.

Guest Editors

Dr. Matthew T. Houdek

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA

Dr. Peter C. Ferguson

Department of Surgery, University of Toronto, Toronto, ON M5G 1X5, Canada

Deadline for manuscript submissions

closed (31 March 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/78983

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)